American Journal of Kidney Diseases
Volume 51, Issue 4 , Pages 594-602 , April 2008

Therapies for Acute Heart Failure in Patients With Reduced Kidney Function: A Community-Based Perspective

  • Robert J. Goldberg, PhD

      Affiliations

    • Department of Community Health, Brown University, Providence, RI
    • Department of Medicine, Division of Cardiovascular Medicine, University of Massachusetts Medical School, Worcester, MA
    • Corresponding Author InformationAddress correspondence to Robert J. Goldberg, PhD, Department of Medicine, Division of Cardiovascular Medicine, University of Massachusetts Medical School, 55 Lake Ave N, Worcester, MA 01655.
    • ,
  • Rovshan M. Ismailov, MD, PhD

      Affiliations

    • Department of Community Health, Brown University, Providence, RI
    • ,
  • Vishnu Patlolla, MD

      Affiliations

    • Department of Medicine, Division of Cardiovascular Medicine, University of Massachusetts Medical School, Worcester, MA
    • ,
  • Darleen Lessard, MS

      Affiliations

    • Department of Medicine, Division of Cardiovascular Medicine, University of Massachusetts Medical School, Worcester, MA
    • ,
  • Frederick A. Spencer, MD

      Affiliations

    • Department of Medicine, Division of Cardiovascular Medicine, University of Massachusetts Medical School, Worcester, MA
    • Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

Received 6 March 2007 ,Accepted 19 November 2007.

References 

  1. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: Prognostic and therapeutic implications from a prospective cohort study. Circulation. 2004;109:1004–1009
  2. Ezekowitz J, McAlister FA, Humphries KH, et al. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol. 2004;44:1587–1592
  3. Bibbins-Domingo K, Lin F, Vittinghoff E, Barrett-Connor E, Grady D, Shlipak MG. Renal insufficiency as an independent predictor of mortality among women with heart failure. J Am Coll Cardiol. 2004;44:1593–1600
  4. Erdmann E, Lechat P, Verkenne P, Wiemann H. Results from post-hoc analyses of the CIBIS II trial: Effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur J Heart Fail. 2001;3:469–479
  5. Shlipak MG, Browner WS, Noguchi H, Massie B, Frances CD, McClellan M. Comparison of the effects of angiotensin converting-enzyme inhibitors and beta blockers on survival in elderly patients with reduced left ventricular function after myocardial infarction. Am J Med. 2001;110:425–433
  6. Shlipak MG. Pharmacotherapy for heart failure in patients with renal insufficiency. Ann Intern Med. 2003;138:917–924
  7. Frances CD, Noguchi H, Massie BM, Browner WS, McClellan M. Are we inhibited? (Renal insufficiency should not preclude the use of ACE inhibitors for patients with myocardial infarction and depressed left ventricular function). Arch Intern Med. 2000;160:2645–2650
  8. Berger AK, Duval S, Manske C, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease. Am Heart J. 2007;153:1064–1073
  9. Goldberg RJ, Spencer FA, Farmer C, Meyer TE, Pezzella S. Incidence and hospital death rates associated with heart failure: A community-wide perspective. Am J Med. 2005;118:728–734
  10. Goldberg RJ, Farmer C, Spencer FA, Pezzella S, Meyer TE. Use of nonpharmacologic treatment approaches in patients with heart failure. Int J Cardiol. 2006;110:348–353
  11. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: The Framingham Study. N Engl J Med. 1971;285:1441–1446
  12. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation (Modification of Diet in Renal Disease Study Group). Ann Intern Med. 1999;130:461–470
  13. McDermott MM, Feinglass J, Lee P, et al. Heart failure between 1986 and 1994: Temporal trends in drug-prescribing practices, hospital readmissions, and survival at an academic medical center. Am Heart J. 1997;134:901–909
  14. Rich MW, Brooks K, Luther P. Temporal trends in pharmacotherapy for congestive heart failure at an academic medical center: 1990-1995. Am Heart J. 1998;135:367–372
  15. Philbin EF. Factors determining angiotensin-converting enzyme inhibitor underutilization in heart failure in a community setting. Clin Cardiol. 1998;21:103–108
  16. Edep ME, Shah NB, Tatoe IM, Massie BM. Differences between primary care physicians and cardiologists in management of congestive heart failure: Relation to practice guidelines. J Am Coll Cardiol. 1997;30:518–526
  17. Massie BM, Armstrong PW, Cleland JG, et al. Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: Results from the ATLAS trial (The Assessment and Treatment with Lisinopril and Survival). Arch Intern Med. 2001;161:165–171
  18. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997;349:747–752
  19. Ljungman S, Kjekshus J, Swedburg K. Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandanavian Enalapril Consensus Study [CONSENSUS] Trial). Am J Cardiol. 1992;70:479–487
  20. Swedberg K, Eneroth P, Kjekshus J, Snapinn S. Effects of enalapril and neuroendocrine activation on prognosis in severe congestive heart failure (follow-up of the CONSENSUS trial) (CONSENSUS Trial Study Group). Am J Cardiol. 1990;66:40D–44D
  21. Bart BA, Ertl G, Held P, et al. Contemporary management of patients with left ventricular systolic dysfunction (Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry). Eur Heart J. 1999;20:1182–1190
  22. Timmermans PB, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 1993;45:205–251
  23. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial—The Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582–1587
  24. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure: A double-blind randomized study. J Am Coll Cardiol. 1995;25:1225–1231
  25. Metra M, Giubbini R, Nodari S, Boldi E, Modena MG, Dei Cas L. Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation. 2000;102:546–551
  26. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure (Randomized Aldactone Evaluation Study Investigators). N Engl J Med. 1999;341:709–717
  27. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525–533
  28. Mehta RH, Montoye CK, Gallogly M, et al. Improving quality of care for acute myocardial infarction: The Guidelines Applied in Practice (GAP) Initiative. JAMA. 2002;287:1269–1276
  29. Banerjee P, Banerjee T, Khand A, Clark AL, Cleland JGF. Diastolic heart failure: Neglected or misdiagnosed?. J Am Coll Cardiol. 2002;39:138–141

 Originally published online as doi:10.1053/j.ajkd.2007.11.021 on February 7, 2008.

PII: S0272-6386(07)01607-1

doi: 10.1053/j.ajkd.2007.11.021

American Journal of Kidney Diseases
Volume 51, Issue 4 , Pages 594-602 , April 2008

Article Tools

* Image Usage & Resolution